We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
Read MoreHide Full Article
Key Takeaways
Casgevy, approved for two blood disorders, continues to gain commercial traction globally.
CRSP's Q2 results may show rising Casgevy sales and ongoing strength from collaboration revenues.
Investors await updates on CTX112, CTX131, CTX310 and CTX320 in ongoing phase I/II studies.
We expect investors to focus on the sales performance of CRISPR Therapeutics’ (CRSP - Free Report) sole-marketed product, Casgevy, and other pipeline updates when the company reports its second-quarter 2025 results.
The Zacks Consensus Estimate for the to-be-reported quarter’s top line is pegged at $6.6 million, while the same for the bottom line is pegged at a loss of $1.47 per share.
Year to date, shares of CRISPR Therapeutics have rallied 64.6% against the industry’s decline of 9.7%.
Image Source: Zacks Investment Research
Let’s see how things might have shaped up before the announcement.
Factors Shaping CRSP's Upcoming Results
CRISPR Therapeutics’ top line currently includes grants and collaboration revenues from its partnership with Vertex Pharmaceuticals (VRTX - Free Report) .
CRSP and partner VRTX’s one-shot gene therapy, Casgevy, was approved in late 2023/early 2024 for two blood disorders — sickle cell disease and transfusion-dependent beta-thalassemia — in the United States and Europe and several other countries.
Casgevy is the first marketed product in CRSP’s portfolio. Vertex leads the global development and commercialization of Casgevy under the terms of the 2021 agreement, with support from CRISPR Therapeutics.
In the last reported quarter, CRSP did not separately mention any royalty/sales revenues related to Casgevy. Vertex recorded $14.2 million in sales from Casgevy in the first quarter of 2025. Casgevy sales surged 77.5% on a sequential basis in the last reported quarter, reflecting strong adoption already.
Sales of Casgevy should be higher in the second quarter of 2025. Our model estimates for CRISPR’s share of the gene therapy sales are pegged at $4.5 million in the second quarter.
Investors will be keen to get more updates related to the commercial progress of Casgevy on the upcoming earnings call.
CRISPR Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. The company is currently focused on the development of two next-generation CAR-T therapy candidates — CTX112 (for CD9-positive B-cell malignancies and autoimmune disorders) and CTX131 (for solid tumors and hematological malignancies) — in separate phase I/II studies. Updates from all these studies are expected on the upcoming earnings call.
CRISPR Therapeutics is also currently studying its first two in-vivo candidates, CTX310 and CTX320, in separate phase I studies targeting ANGPTL3 and lipoprotein(a), respectively.
Last month, the company announced updated data from the first 10 patients across the first four cohorts of the phase I study on CTX310. The data showed that a single dose of CTX310 demonstrated dose-dependent decreases in low-density lipoprotein (LDL) and triglyceride (TG) levels, with peak reduction of up to 82% in TG and up to 86% in LDL.
Operating expenses are most likely to have increased in the to-be-reported quarter due to higher collaboration expenses.
CRSP's Earnings Surprise History
CRISPR Therapeutics has a mixed history of earnings surprises. The company beat on earnings in two of the trailing four quarters while missing the same on the remaining two occasions, delivering an average surprise of 13.16%. In the last reported quarter, CRSP delivered a negative earnings surprise of 24.41%.
Our proven model does not conclusively predict an earnings beat for CRISPR Therapeutics this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
CRSP’s Earnings ESP: CRISPR Therapeutics has an Earnings ESP of -11.09% as the Most Accurate Estimate currently stands at a loss of $1.63 per share and the Zacks Consensus Estimate is pegged at a loss of $1.47 per share.
CRSP’s Zacks Rank: CRISPR Therapeutics has a Zacks Rank #4 (Sell) at present.
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +475.00% and a Zacks Rank #2 at present.
Shares of EXAS have declined 13.7% year to date. EXAS beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 48.79%. Exact Sciences is scheduled to report second-quarter results on Aug. 6, after market close.
Alkermes (ALKS - Free Report) has an Earnings ESP of +4.94% and a Zacks Rank #3 at present.
Shares of ALKS have lost 9.1% year to date. ALKS beat on earnings in one of the last four quarters and missed in the other three, delivering an average negative surprise of 8.24%. Alkermes will report second-quarter results on July 29, before market open.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
Key Takeaways
We expect investors to focus on the sales performance of CRISPR Therapeutics’ (CRSP - Free Report) sole-marketed product, Casgevy, and other pipeline updates when the company reports its second-quarter 2025 results.
The Zacks Consensus Estimate for the to-be-reported quarter’s top line is pegged at $6.6 million, while the same for the bottom line is pegged at a loss of $1.47 per share.
Year to date, shares of CRISPR Therapeutics have rallied 64.6% against the industry’s decline of 9.7%.
Image Source: Zacks Investment Research
Let’s see how things might have shaped up before the announcement.
Factors Shaping CRSP's Upcoming Results
CRISPR Therapeutics’ top line currently includes grants and collaboration revenues from its partnership with Vertex Pharmaceuticals (VRTX - Free Report) .
CRSP and partner VRTX’s one-shot gene therapy, Casgevy, was approved in late 2023/early 2024 for two blood disorders — sickle cell disease and transfusion-dependent beta-thalassemia — in the United States and Europe and several other countries.
Casgevy is the first marketed product in CRSP’s portfolio. Vertex leads the global development and commercialization of Casgevy under the terms of the 2021 agreement, with support from CRISPR Therapeutics.
In the last reported quarter, CRSP did not separately mention any royalty/sales revenues related to Casgevy. Vertex recorded $14.2 million in sales from Casgevy in the first quarter of 2025. Casgevy sales surged 77.5% on a sequential basis in the last reported quarter, reflecting strong adoption already.
Sales of Casgevy should be higher in the second quarter of 2025. Our model estimates for CRISPR’s share of the gene therapy sales are pegged at $4.5 million in the second quarter.
Investors will be keen to get more updates related to the commercial progress of Casgevy on the upcoming earnings call.
CRISPR Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. The company is currently focused on the development of two next-generation CAR-T therapy candidates — CTX112 (for CD9-positive B-cell malignancies and autoimmune disorders) and CTX131 (for solid tumors and hematological malignancies) — in separate phase I/II studies. Updates from all these studies are expected on the upcoming earnings call.
CRISPR Therapeutics is also currently studying its first two in-vivo candidates, CTX310 and CTX320, in separate phase I studies targeting ANGPTL3 and lipoprotein(a), respectively.
Last month, the company announced updated data from the first 10 patients across the first four cohorts of the phase I study on CTX310. The data showed that a single dose of CTX310 demonstrated dose-dependent decreases in low-density lipoprotein (LDL) and triglyceride (TG) levels, with peak reduction of up to 82% in TG and up to 86% in LDL.
Operating expenses are most likely to have increased in the to-be-reported quarter due to higher collaboration expenses.
CRSP's Earnings Surprise History
CRISPR Therapeutics has a mixed history of earnings surprises. The company beat on earnings in two of the trailing four quarters while missing the same on the remaining two occasions, delivering an average surprise of 13.16%. In the last reported quarter, CRSP delivered a negative earnings surprise of 24.41%.
CRISPR Therapeutics AG Price and EPS Surprise
CRISPR Therapeutics AG price-eps-surprise | CRISPR Therapeutics AG Quote
What Our Model Predicts for CRSP Stock
Our proven model does not conclusively predict an earnings beat for CRISPR Therapeutics this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
CRSP’s Earnings ESP: CRISPR Therapeutics has an Earnings ESP of -11.09% as the Most Accurate Estimate currently stands at a loss of $1.63 per share and the Zacks Consensus Estimate is pegged at a loss of $1.47 per share.
CRSP’s Zacks Rank: CRISPR Therapeutics has a Zacks Rank #4 (Sell) at present.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks With the Favorable Combination
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +475.00% and a Zacks Rank #2 at present.
Shares of EXAS have declined 13.7% year to date. EXAS beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 48.79%. Exact Sciences is scheduled to report second-quarter results on Aug. 6, after market close.
Alkermes (ALKS - Free Report) has an Earnings ESP of +4.94% and a Zacks Rank #3 at present.
Shares of ALKS have lost 9.1% year to date. ALKS beat on earnings in one of the last four quarters and missed in the other three, delivering an average negative surprise of 8.24%. Alkermes will report second-quarter results on July 29, before market open.